Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Might be getting ready for some volume. $NUVPF
Green day VANC/NUVPF? Getting closer to that legalization date. Ready to see some more accumulation and shares are scarce down here.
Over 4000? Ready to double that! :)
LOOK FOR RED TO SEE 4K ACCOUNTS ..
VANC Pharmaceuticals Inc. (“VANC”) (TSXV: VANC, OTCQB: NUVPF) is pleased to announce that it has entered into a sales broker agreement with Pinnacle Pharmaceutics Ltd. (“Pinnacle”), pursuant to which Pinnacle will serve as VANC’s exclusive sales broker in Ontario, Québec and Atlantic Canada (the “Territory”) in respect of VANC’s over-the-counter and behind-the-counter products and point of care technologies.
Pursuant to the sales agreement, Pinnacle has agreed to market, sell and distribute VANC’s products in the Territory, and to work with VANC to promote value-added products and services for pharmacies.
Pinnacle is a leading Canadian manufacturer’s agent specializing in sales and marketing for pharmacy products. Pinnacle is a leading broker in the Canadian drugstore industry, with retail sales staff across Ontario and a network of brokers in other markets throughout Canada. Pinnacle services over 4,000 accounts nationally, focusing on pharmacy detailing and promoting the unique selling points of the products it represents.
“We are very excited to be working with Pinnacle. Based on their track record in the industry, we’re optimistic that they will drive product sales and increase awareness of our point-of-care testing technologies in Eastern Canada,” said Bob Rai, CEO of VANC.
Tom Measor, President of Pinnacle added, “This is an excellent opportunity to partner with a reputable and promising company such as VANC. With over 20 years of experience and a team of dedicated representatives, we believe that we have the tools to effectively market VANC’s products and increase brand success and market penetration.”
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to support their evolving business models and expanding role as front-line healthcare providers.
I'vee never been much for ibox maint thats why it's so sparse... I will add the new links in there but that's about all I can promise. Glta
Hi y'all, new here... I couldn't help but notice
that your intro-box is a bit sparse.
Can I maybe offer a few suggestions, assuming this stuff is still relevant, of course :).
Website: http://www.vancpharm.com/
News: http://www.vancpharm.com/category/news-releases/
Financials: http://www.vancpharm.com/investor-relations/financials/
Presentation: http://www.vancpharm.com/wp-content/uploads/2017/04/2016-06-22-AGM-Presentation.pdf
Facebook: https://www.facebook.com/vancpharm
Twitter: https://twitter.com/Vanc_Pharm
Linked-in: https://www.linkedin.com/company/vanc-pharmaceuticals-inc-
Yes agreed. If you think about it though, the pharmacies already have the footprint, the real estate, the consumer trust... Common sense for Canada! ;)
NUVPF "positioned to sell medicinal cannabis through pharmacies"
Awesome, great timing, think we're in for a tide here, gltya amigos
Cool .. either way will do good !!
If Canadian pharmacies end up embracing cannabis quickly then I think the dispensary model could potentially be rendered obsolete.. just purely my speculation, mixed with optimism.
Let the accumulation continue! $NUVPF
EMHTF PAYING .33 a share ...
This is still cheap
? Think they also whole sale me for dispensary and storefronts ?
Highest volume day ever .... bottom in hold tight boys !!!!
Lookin REAL good...LOL $NUVPF
Looking great brought the amigos with me ...lol
Agreed. Should've clarified. Would like to know how small the float actually is. :) $NUVPF
SHRS OUT: 28,452,123
I would guess the available float is less than 10 million. I think it is locked up by insiders who know where its going... Dollars.
Emerald Health Therapeutics to Launch Award-Winning Endocannabinoid Based Products into Canadian Grocery, Natural Health Product, and Pharmacy StoresPress Release | 04/17/2018
New joint venture, Emerald Health Naturals, secures exclusive Canadian rights to sell proprietary non-cannabis health products that support the human endocannabinoid system
Initiative leverages natural health product development, marketing and sales expertise of Emerald Health Bioceuticals, VANC Pharmaceuticals and GAB Innovations to establish brand and sales in strategic distribution channels
VICTORIA, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (EHT) (TSX-V:EMH) (OTCQX:EMHTF) (Frankfurt:TBD)?launched today a multi-pronged program to market and sell a proprietary, award-winning non-cannabis line of endocannabinoid-supporting nutritional products in Canadian grocery, natural health product, and pharmacy stores. EHT has entered into a 51:49 joint venture, to be called Emerald Health Naturals (EHN), with San Diego-based Emerald Health Bioceuticals, Inc. (EHB). EHN has secured exclusive Canadian marketing and sales rights to EHB’s unique nutritional supplements, which use non-cannabis, non-psychoactive plant-based ingredients to provide potentially beneficial support to the body’s endocannabinoid system.
In this initiative, EHN has agreed to acquire the assets of GAB Innovations (GAB) and has granted non-exclusive sub-distribution rights to VANC Pharmaceuticals (VANC). Both GAB and VANC have established networks and a history of sales success in the natural health product and pharmacy channels. Gaetano Morello, ND, the founder of GAB, has been appointed CEO of EHN.
Market research commissioned by EHT identified that approximately 6 of 10 current legal cannabis users also use natural health products. This strong consumer overlap between the two markets creates a unique opportunity for EHT to establish its health brand and begin sales of endocannabinoid-supporting products in natural health product channels. These channels are not expected to be authorized to sell cannabis under the anticipated Canadian federal cannabis regulations for recreational use expected in 2018. If these channels are approved in the future, EHT would be well positioned to leverage its brand and channel presence to introduce its cannabis-based products into these channels.
“As familiar and trusted sources of health products, we believe that pharmacy, natural health product, and grocery stores will become important channels for products that beneficially affect the endocannabinoid system,” said Chris Wagner, CEO of EHT. “This acclaimed non-cannabis product line gives us first-mover advantage in these channels and positioning if they are approved to sell cannabis-based products in the future. These channels would also be ideal for new products we are developing around advancements in formulation, delivery, and dosing.”
“We were recently honored with the Best New Supplement Award at one of the largest natural product trade shows, a testament to the quality and innovativeness of our product line,” noted Jade Beutler, CEO of EHB. “We look forward to introducing these natural health products to the Canadian marketplace, which along with other legal cannabis markets is showing tremendous appetite for non-psychoactive products that may provide wellness benefits.”
EHT is leveraging multiple relationships to launch this initiative:
Formed a joint venture with San Diego-based Emerald Health Bioceuticals. EHT will receive 51% of the shares of EHN in exchange for an investment of $5,000,000. EHB will receive 49% of the shares of EHN in exchange for granting the joint venture exclusive Canadian distribution rights with respect to EHB’s product line.
EHB developed and launched its over-the-counter product line of cannabis-free nutritional supplements in the U.S. The products feature PhytoCann-Complex™, EHB’s proprietary formulation designed to support the body’s endocannabinoid system and its central role in the orchestration, maintenance, and balance of health and wellbeing. The products include Endo SleepTM, Endo InflameTM, Endo BrainTM, Endo BlissTM, Endo CalmTM.
EHB’s management and scientific advisory board (SAB) comprise experts in natural health medicine, product development, and marketing. They have decades of experience working with active ingredients, desired formulations, delivery and dosage forms, and have access to source ingredients and industrial-scale, pharmaceutical quality manufacturing. For example, the SAB includes Michael T. Murray, ND, a leading authority on natural medicine, and Giovanni Appendino, PhD, a thought leader who has researched cannabis and cannabinoids for over 15 years. CEO Jade Beutler and the EHB leadership team have built significant, commercially successful natural health product brands.
EHB is a 70%-owned subsidiary of Emerald Health Sciences Inc. (Sciences), which also owns approximately 37% of the issued and outstanding shares of EHT. There will be no change in the share ownership of EHT by Sciences as a result of the joint venture. The joint venture with EHB was approved by the independent directors of EHT.
Appointed Gaetano Morello, ND, as CEO of EHN. Dr. Morello is a clinician at the Complex Chronic Disease Program at BC Women’s Hospital in Vancouver and a private practice in West Vancouver. He treats complex chronic diseases including fibromyalgia, chronic fatigue syndrome, myalgic encephalomyelitis, and chronic lyme disease. He has seen first-hand not only the benefits of authorized cannabis on this population but also other plant extracts targeting the endocannabinoid system. He serves on the Quality Assurance Committee for the College of Naturopathic Physicians of British Columbia and other health and medical panels. Dr. Morello has a B.Sc. in Cell Biology/Nutrition from the University of British Columbia and a Doctorate in Naturopathic Medicine from Bastyr University.
EHN has acquired certain assets of GAB, a company founded by Dr. Morello that has been a distributor of nutritional supplements into natural health channels since 1996. GAB has represented some of North America’s leading manufacturers of natural health supplements including Enzymatic Therapy, a leading manufacturer of natural supplements; Thorne Research, a leading physician brand in both Canada and the U.S.; as well as Terry Naturally, Wisdom Sweet Leaf, and others. GAB has represented hundreds of SKUs to a network of over 2,000 health food and pharmacy stores across the country. GAB recently sold its proprietary Sealicious® omega-3 product line to Natural Factors, one of Canada’s largest producers of natural supplements.
Granted VANC Pharmaceuticals Inc. (TSX-V:VANC) (OTCQB:NUVPF) a non-exclusive right to distribute EHN’s endocannabinoid-supporting products to Canadian pharmacies. VANC has a well-established sales team and key relationships with Canada’s largest pharmaceutical wholesalers as well as pharmacy and grocery chains. VANC will concurrently issue to EHN 3,030,303 warrants to purchase shares of VANC.
“We believe the sales potential for cannabis products in pharmacies is significant and providing these products through the pharmacy channel would be a natural fit as pharmacists play a key role in promoting public safety through education and awareness. We will take a lead role to develop this channel with Emerald Health Naturals, starting with these cannabis-free endocannabinoid-supporting products,” said Bob Rai, CEO and Director of VANC.
“Our mission is to broadly realize the medicinal benefits of a range of products that interact with the endocannabinoid system, which plays a vital role in modulating key functions of the human body. Emerald Health Bioceuticals and its internationally recognized advisors have created a unique product line that we believe can assist the endocannabinoid system in its role,” said Dr. Morello, CEO of EHN. “As a practitioner of natural medicine for over 26 years, and having assessed hundreds of patients using legally authorized cannabis, I believe Canada’s steps to legalize recreational cannabis will be beneficial for patients with many medical conditions. I am excited about the potential of EHT’s cannabis and non-cannabis products, and to take on a role to help realize the medicinal and commercial potential of these products.”
Completion of the transactions set out in this press release are subject to the approval of the TSX Venture Exchange.
Join us on our journey of making lives better through cannabis science.
About the Endocannabinoid System (ECS)
The ECS is a biological system with a vital role in regulating human health and disease. A lack of endocannabinoid “tone” may have adverse consequences in various physiological processes. The ECS is activated by endocannabinoids produced naturally in the body, but also by cannabis or non-cannabis plant-based cannabinoids that mimic those produced in the body. Phyto-CannTM Complex is formulated with non-cannabis herbal and botanical cannabinoids that may favorably impact the ECS, along with health and wellness.
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, VANC’s goal is to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
About Emerald Health Therapeutics
Emerald Health Therapeutics (TSX-V:EMH) (OTCQX:EMHTF) (Frankfurt:TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. It is adding a 500,000 ft2 greenhouse in Metro Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a joint venture with Village Farms International, Inc. that is converting an existing 1.1 million ft2 greenhouse in Delta, BC to grow cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald Health Therapeutics and Emerald Health Bioceuticals are both part of the Emerald Health group, which includes multiple companies focused on developing cannabis and cannabinoid products with potential wellness and medical benefits.
Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill
Ray Lagace
CFO
Investor Relations Manager
(800) 757 3536 Ext. #5
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Nice day so far, maybe she is waking up. $1 could happen very fast.
Peeps sleepin on this one imho. $NUVPF
Around 28 million....tiny imo.
All it will take is one or two investment funds to begin accumulating NUVPF and it will be $100M market cap very quickly. I would guess the float is quite small.
Agreed. Long hold here, waiting for multiple dollars at a minimum, based on current share structure. $NUVPF
All things considered, market cap for VANC is deeply undervalued at these levels. If EMH channels majority of pharmacy sales thru NUVPF then sales will explode and this will be an epic runner.
These guys are going to hit the ground running. Good luck loading cheap after legalization. $NUVPF
Pinnacle services over 4,000 accounts nationally, focusing on pharmacy detailing and promoting the unique selling points o
EHN has agreed to acquire the assets of GAB Innovations (GAB) and has granted non-exclusive sub-distribution rights to VANC Pharmaceuticals (VANC). Both GAB and VANC have established networks and a history of sales success in the natural health product and pharmacy channels. Gaetano Morello, ND, the founder of GAB, has been appointed CEO of EHN.
VANC Announces Exclusive Sales Broker Agreement With Pinnacle PharmaceuticsPress Release | 04/09/2018
VANCOUVER, British Columbia, April 09, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) is pleased to announce that it has entered into a sales broker agreement with Pinnacle Pharmaceutics Ltd. (“Pinnacle”), pursuant to which Pinnacle will serve as VANC’s exclusive sales broker in Ontario, Québec and Atlantic Canada (the “Territory”) in respect of VANC’s over-the-counter and behind-the-counter products and point of care technologies.
Pursuant to the sales agreement, Pinnacle has agreed to market, sell and distribute VANC’s products in the Territory, and to work with VANC to promote value-added products and services for pharmacies.
Pinnacle is a leading Canadian manufacturer’s agent specializing in sales and marketing for pharmacy products. Pinnacle is a leading broker in the Canadian drugstore industry, with retail sales staff across Ontario and a network of brokers in other markets throughout Canada. Pinnacle services over 4,000 accounts nationally, focusing on pharmacy detailing and promoting the unique selling points of the products it represents.
“We are very excited to be working with Pinnacle. Based on their track record in the industry, we’re optimistic that they will drive product sales and increase awareness of our point-of-care testing technologies in Eastern Canada,” said Bob Rai, CEO of VANC.
Tom Measor, President of Pinnacle added, “This is an excellent opportunity to partner with a reputable and promising company such as VANC. With over 20 years of experience and a team of dedicated representatives, we believe that we have the tools to effectively market VANC’s products and increase brand success and market penetration.”
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to support their evolving business models and expanding role as front-line healthcare providers.
On behalf of:
VANC Pharmaceuticals Inc.
Bob Rai
Director and CEO
For further information, please contact Bob Rai at 604-247-2639.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
https://www.otcmarkets.com/stock/NUVPF/news/VANC-Announces-Exclusive-Sales-Broker-Agreement-With-Pinnacle-Pharmaceutics?id=188484
Emerald Health Therapeutics to Launch Award-Winning Endocannabinoid Based Products into Canadian Grocery, Natural Health Product, and Pharmacy Stores
New joint venture, Emerald Health Naturals, secures exclusive Canadian rights to sell proprietary non-cannabis health products that support the human endocannabinoid system
Initiative leverages natural health product development, marketing and sales expertise of Emerald Health Bioceuticals, VANC Pharmaceuticals and GAB Innovations to establish brand and sales in strategic distribution channels
VICTORIA, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (EHT) (TSX-V:EMH) (OTCQX:EMHTF) (Frankfurt:TBD)?launched today a multi-pronged program to market and sell a proprietary, award-winning non-cannabis line of endocannabinoid-supporting nutritional products in Canadian grocery, natural health product, and pharmacy stores. EHT has entered into a 51:49 joint venture, to be called Emerald Health Naturals (EHN), with San Diego-based Emerald Health Bioceuticals, Inc. (EHB). EHN has secured exclusive Canadian marketing and sales rights to EHB’s unique nutritional supplements, which use non-cannabis, non-psychoactive plant-based ingredients to provide potentially beneficial support to the body’s endocannabinoid system.
In this initiative, EHN has agreed to acquire the assets of GAB Innovations (GAB) and has granted non-exclusive sub-distribution rights to VANC Pharmaceuticals (VANC). Both GAB and VANC have established networks and a history of sales success in the natural health product and pharmacy channels. Gaetano Morello, ND, the founder of GAB, has been appointed CEO of EHN.
Market research commissioned by EHT identified that approximately 6 of 10 current legal cannabis users also use natural health products. This strong consumer overlap between the two markets creates a unique opportunity for EHT to establish its health brand and begin sales of endocannabinoid-supporting products in natural health product channels. These channels are not expected to be authorized to sell cannabis under the anticipated Canadian federal cannabis regulations for recreational use expected in 2018. If these channels are approved in the future, EHT would be well positioned to leverage its brand and channel presence to introduce its cannabis-based products into these channels.
“As familiar and trusted sources of health products, we believe that pharmacy, natural health product, and grocery stores will become important channels for products that beneficially affect the endocannabinoid system,” said Chris Wagner, CEO of EHT. “This acclaimed non-cannabis product line gives us first-mover advantage in these channels and positioning if they are approved to sell cannabis-based products in the future. These channels would also be ideal for new products we are developing around advancements in formulation, delivery, and dosing.”
“We were recently honored with the Best New Supplement Award at one of the largest natural product trade shows, a testament to the quality and innovativeness of our product line,” noted Jade Beutler, CEO of EHB. “We look forward to introducing these natural health products to the Canadian marketplace, which along with other legal cannabis markets is showing tremendous appetite for non-psychoactive products that may provide wellness benefits.”
EHT is leveraging multiple relationships to launch this initiative:
Formed a joint venture with San Diego-based Emerald Health Bioceuticals. EHT will receive 51% of the shares of EHN in exchange for an investment of $5,000,000. EHB will receive 49% of the shares of EHN in exchange for granting the joint venture exclusive Canadian distribution rights with respect to EHB’s product line.
EHB developed and launched its over-the-counter product line of cannabis-free nutritional supplements in the U.S. The products feature PhytoCann-Complex™, EHB’s proprietary formulation designed to support the body’s endocannabinoid system and its central role in the orchestration, maintenance, and balance of health and wellbeing. The products include Endo SleepTM, Endo InflameTM, Endo BrainTM, Endo BlissTM, Endo CalmTM.
EHB’s management and scientific advisory board (SAB) comprise experts in natural health medicine, product development, and marketing. They have decades of experience working with active ingredients, desired formulations, delivery and dosage forms, and have access to source ingredients and industrial-scale, pharmaceutical quality manufacturing. For example, the SAB includes Michael T. Murray, ND, a leading authority on natural medicine, and Giovanni Appendino, PhD, a thought leader who has researched cannabis and cannabinoids for over 15 years. CEO Jade Beutler and the EHB leadership team have built significant, commercially successful natural health product brands.
EHB is a 70%-owned subsidiary of Emerald Health Sciences Inc. (Sciences), which also owns approximately 37% of the issued and outstanding shares of EHT. There will be no change in the share ownership of EHT by Sciences as a result of the joint venture. The joint venture with EHB was approved by the independent directors of EHT.
Appointed Gaetano Morello, ND, as CEO of EHN. Dr. Morello is a clinician at the Complex Chronic Disease Program at BC Women’s Hospital in Vancouver and a private practice in West Vancouver. He treats complex chronic diseases including fibromyalgia, chronic fatigue syndrome, myalgic encephalomyelitis, and chronic lyme disease. He has seen first-hand not only the benefits of authorized cannabis on this population but also other plant extracts targeting the endocannabinoid system. He serves on the Quality Assurance Committee for the College of Naturopathic Physicians of British Columbia and other health and medical panels. Dr. Morello has a B.Sc. in Cell Biology/Nutrition from the University of British Columbia and a Doctorate in Naturopathic Medicine from Bastyr University.
EHN has acquired certain assets of GAB, a company founded by Dr. Morello that has been a distributor of nutritional supplements into natural health channels since 1996. GAB has represented some of North America’s leading manufacturers of natural health supplements including Enzymatic Therapy, a leading manufacturer of natural supplements; Thorne Research, a leading physician brand in both Canada and the U.S.; as well as Terry Naturally, Wisdom Sweet Leaf, and others. GAB has represented hundreds of SKUs to a network of over 2,000 health food and pharmacy stores across the country. GAB recently sold its proprietary Sealicious® omega-3 product line to Natural Factors, one of Canada’s largest producers of natural supplements.
Granted VANC Pharmaceuticals Inc. (TSX-V:VANC) (OTCQB:NUVPF) a non-exclusive right to distribute EHN’s endocannabinoid-supporting products to Canadian pharmacies. VANC has a well-established sales team and key relationships with Canada’s largest pharmaceutical wholesalers as well as pharmacy and grocery chains. VANC will concurrently issue to EHN 3,030,303 warrants to purchase shares of VANC.
“We believe the sales potential for cannabis products in pharmacies is significant and providing these products through the pharmacy channel would be a natural fit as pharmacists play a key role in promoting public safety through education and awareness. We will take a lead role to develop this channel with Emerald Health Naturals, starting with these cannabis-free endocannabinoid-supporting products,” said Bob Rai, CEO and Director of VANC.
“Our mission is to broadly realize the medicinal benefits of a range of products that interact with the endocannabinoid system, which plays a vital role in modulating key functions of the human body. Emerald Health Bioceuticals and its internationally recognized advisors have created a unique product line that we believe can assist the endocannabinoid system in its role,” said Dr. Morello, CEO of EHN. “As a practitioner of natural medicine for over 26 years, and having assessed hundreds of patients using legally authorized cannabis, I believe Canada’s steps to legalize recreational cannabis will be beneficial for patients with many medical conditions. I am excited about the potential of EHT’s cannabis and non-cannabis products, and to take on a role to help realize the medicinal and commercial potential of these products.”
Completion of the transactions set out in this press release are subject to the approval of the TSX Venture Exchange.
Join us on our journey of making lives better through cannabis science.
About the Endocannabinoid System (ECS)
The ECS is a biological system with a vital role in regulating human health and disease. A lack of endocannabinoid “tone” may have adverse consequences in various physiological processes. The ECS is activated by endocannabinoids produced naturally in the body, but also by cannabis or non-cannabis plant-based cannabinoids that mimic those produced in the body. Phyto-CannTM Complex is formulated with non-cannabis herbal and botanical cannabinoids that may favorably impact the ECS, along with health and wellness.
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, VANC’s goal is to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
About Emerald Health Therapeutics
Emerald Health Therapeutics (TSX-V:EMH) (OTCQX:EMHTF) (Frankfurt:TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. It is adding a 500,000 ft2 greenhouse in Metro Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a joint venture with Village Farms International, Inc. that is converting an existing 1.1 million ft2 greenhouse in Delta, BC to grow cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald Health Therapeutics and Emerald Health Bioceuticals are both part of the Emerald Health group, which includes multiple companies focused on developing cannabis and cannabinoid products with potential wellness and medical benefits.
Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill
Ray Lagace
CFO
Investor Relations Manager
(800) 757 3536 Ext. #5
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca
Hell yea brother!
OUR NEW WEBSITE ...
https://www.corozonplatform.com/
VANC Announces Agreement for Acquisition of Corozon Platform
VANCOUVER, British Columbia, April 11, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) is pleased to announce it has entered into a defintive agreement with Corozon Consulting Corporation (“Corozon Consulting”) for the acquisition of the Corozon Platform (“Platform”). The Platform (www.corozonplatform.com) is an innovative portal designed to provide front line community pharmacists with the knowledge and tools to implement practice change and enhance their professional service programs. It is the first online service of its kind in Canada, addressing the lack of infrastructure to support pharmacy program and service delivery. The Platform benefits pharmacists by enabling them to offer sustainable and tailored care to their patients, potentially increasing their billables and improving competitiveness.
The Platform itself consists of two complementary modules. 'Corozon Academy' offers practical professional education for community pharmacists. The Academy uses short video vignettes hosted by experts in different therapeutic areas to teach pharmacists how to implement, operationalize, and monetize unique clinical services. 'Corozon Hardware' is an e-commerce portal that allows pharmacists to order point-of-care diagnostic devices and supplies. Through these two modules the Platform provides easy access to the latest point-of-care diagnostic devices and also extensive information on how to implement these devices into daily pharmacy practice.
“The unique clinical programs, easy to navigate site, and ready to use tools have quickly made the Corozon Platform the go to site for pharmacists looking to change their practice” says Bryan Gray, managing partner of Corozon Consulting. “The platform aligns well with VANC Pharmaceuticals’ new strategic direction.”
“The Corozon Platform furthers our position as a leader in point-of-care technology for community pharmacies. It will also help to promote VANC’s current portfolio, including the INSTI HIV Antibody Test and our HealthTab system, to the large number of pharmacists already using the site, as well as serve as an additional distribution channel and revenue source for the company,” says VANC CEO Bob Rai.
Pursuant to the terms of the definitive agreement, the purchase price payable by VANC to Corozon Consulting in respect of the Platform will be satisfied by the payment of $50,000 in cash, which will be paid in twelve (12) equal monthly installments following the closing date and the issuance of 909,090 common shares in the capital of VANC at a deemed price of $0.22 per common share, issuable on the closing date (the “Payment Shares”). The Payment Shares to be issued under the transaction will be subject to a four month and one day hold period pursuant to applicable securities laws. In addition, 75% of the Payment Shares will be subject to a resale restriction for a period of 12 months after the closing date. Closing of the acquisition is subject to customary closing conditions, including receipt of TSX Venture Exchange approval.
About Corozon:
Corozon® is an innovative consulting firm comprised of a team of pharmacy leaders and award winning pharmacists. Corozon® is committed to supporting the pharmaceutical industry in developing, testing, and implementing novel clinical programs into community pharmacy practice. Given the rapidly evolving scope of practice, changing legislation, and transforming consumer demand, our team, armed with its unique solution portfolio, is positioned to facilitate navigation in this environment.
www.corozonconsulting.com
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
www.vancpharm.com
For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com .
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bob Rai, Director and CEO
Let's go Cheap...ride this one to $2+ ! $NUVPF
Im ready for a dolla holla
Why This Cannabis Producer Could Emerge as the Apple Inc of the Industry
http://wallst-news.com/cannabis-producer-emerge-apple-inc-industry/?utm_source=icnative&utm_medium=cpc&utm_campaign=ic_native
I think we are very undervalued here, so I am adding the dip here bit by bit. If NUVPF becomes the major pharmacy distribution partner for EMH cannabis derivatives and oils then it seems to me that $1 should be easy on this SS IMO.
Looks like $1 here easy ?
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
307
|
Created
|
07/20/15
|
Type
|
Free
|
Moderators |
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) Board of Directors provided guidance on future company direction and initiatives today.
“In 2017 VANC had begun to anticipate secular changes affecting the generic and community pharmacy industries,” stated Mr. Bob Rai, CEO of VANC. “These changes included the trend towards increased funded participation by pharmacists in healthcare treatment of Canadians as well as dramatically shrinking margins on generic drugs. Our recent strategic partnerships, acquisitions and key personnel changes are a direct reflection of our vision, with a clear focus on growing beyond generics to provide pharmacists with innovative, value-added products, services and information to support their evolving business models and expanding role as front-line healthcare providers,” concluded Mr. Rai.
Concurrent with VANC’s new focus, the company will be reducing its generic portfolio over the next several months. Emerging opportunities in new healthcare sectors and the diminished ability to profit from generic sales drove this strategic decision. The realignment will provide existing products and services with increased focus and resources. This will also drive the expansion of a portfolio of high-margin over the counter (OTC) and point of care (POC) testing products and services that offer unique value to pharmacists, their patients, and consumers.
VANC is expanding its portfolio with announcements of strategic partnerships with Emerald, acquisition of the Corozon Platform, and plans to increase deployment of and expand offerings associated with HealthTab.
The recently announced strategic partnership with Emerald enables VANC to compete in the emerging medical cannabis sector with a line of endocannabinoid enhancers and with the potential to distribute medical cannabis to pharmacies when that avenue of sales is legalized.
“With a renewed focus on high-margin OTC/BTC product development, in addition to our recently announced partnership with Emerald Health, we anticipate generating increased sales and profitability in this pillar of the business in 2018,” explained Mr. Rai. “This shift in focus has also allowed us to engage with sales brokers across Canada, providing greater coverage to our products.”
The Corozon Platform, acquired in April 2018, offers a variety of functionalities including e-learning, e-commerce and potentially promotional modules. These capabilities ideally position it to serve as an anchor for this pillar of the business, functioning as an educational tool and distribution channel for a number of VANC products, including those the company will distribute for Emerald.
Mr. Rai added: “We will be able to leverage the Platform to promote our latest offerings and educate pharmacists on how to use them effectively. It will serve to drive our relationships with pharmacists and will also be a powerful retention tool. Through Corozon, we can efficiently market new services and products directly to the pharmacist.”
HealthTab will form the core of VANC’s future expansion of its point of care pharmacy screening tests to empower pharmacists and improve patient health. HealthTab as it is today will provide pharmacists with a platform to integrate precise blood chemistry into billable medicine reviews for patients in a timely and convenient manner.
“Our HealthTab service is based on a unique technology initially developed to provide a lab quality yet simple test for astronauts on the International Space Station. VANC can now provide this service to the general population. It will change how patients manage their health. It will also benefit the community by serving as a simple screening tool to detect serious conditions such as kidney failure or high cholesterol,” said Mr. Rai.
HealthTab systems have already been launched with strategic community pharmacy pilot programs in BC and Ontario. Furthermore, commitments for additional deployments have been secured and are scheduled for launch in Q2 2018. Additional tests to complement those currently offered by the HealthTab framework are in development and will make it best in class in terms of scope and accessibility to patients.
“The Emerald investment and licensing and the HealthTab and Corozon Platform acquisitions represent significant first steps in repositioning VANC. Further steps are being taken to create the structure and branding that will drive the evolution of our business to a new level in 2018,” concluded Mr. Rai.
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing, and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bob Rai, Director, and CEO
604-247-2639
info@vancpharm.com
www.vancpharm.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |